Is there anything GLP-1 agonist drugs cannot do?
Every other month, researchers find new uses for GLP-1 agonist drugs, like Mounjaro and Ozempic — now even as a treatment for substance abuse. It's
Every other month, researchers find new uses for GLP-1 agonist drugs, like Mounjaro and Ozempic — now even as a treatment for substance abuse. It's classic drug repurposing, a technique that saved lives during COVID. The list of uses for GLP-1 agonist drugs keeps growing: It started as a treatment for type 2 diabetes, then got hyped as a weight-loss jab. There's also evidence that GLP-1 agonists, like semaglutide and tirzepatide — sold as Mounjaro, Ozempic, Wegovy and Zepound lower the risk of cardiovascular diseases protect the kidney and the liver, reduce inflammation and pain, prevent addiction and substance abuse, help people with arthritis and those with sleep apnea. Take a 30,000ft view, and you will see a classic case of what's known in the trade as drug repurposing. That's one drug with multiple uses. Repurposing drugs in a health crisis What may seem to some like a cunning way to cash in on an already popular drug is to others a cost-effective, time-efficient way to save lives. The COVID-19 pandemic is a case in point: consider the drugs dexamethasone and baricitinib. When COVID hit, dexamethasone and baricitinib already existed. They are used to treat inflammation (swelling). Dexamethasone has broad applications — it can be used for arthritis, asthma, blood or bone marrow problems, kidney problems, skin conditions, and acute cases of multiple sclerosis. India's wedding economy driving a weight-loss drug boom To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Baricitinib is used to treat moderate to severe rheumatoid arthritis, moderate to severe atopic dermatitis and severe alopecia areata, an autoimmune disease that attacks the hair (it causes hair loss).
And then doctors tried these drugs to treat inflammation in COVID patients — this was before and in the early stages of COVID vaccines. In 2021, the UK's Health Service reported that dexamethasone saved 22,000 lives in the UK and an estimated one million worldwide. Meanwhile, baricitinib controls elevated cytokine levels and inflammation. During COVID, doctors and researchers observed "cytokine storms" in patients — that's when the immune system becomes overactive, ultimately causing severe inflammation. Following these experiences during COVID, the European Commission planned to increase support for drug repurposing to search for treatments for cancer. A health warning on repurposed drugs None of the above should be read to suggest — and it is not DW's recommendation — that anyone use GLP-1 agonists, or any other drug, to treat any "off label"/non-approved condition, without personal, professional medical advice. There are risks in the use of any medication, and as the uses of GLP-1s have increased, for instance, so too have lesser-known risks emerged. It should also be no surprise that GLP-1 agonists have such universal health benefits. If the drugs can help you lose weight, or stop you gaining it, reduce addictive behavior, then they will also lower the risk of type 2 diabetes — which is largely caused by "lifestyle choices" like overeating — and that, in turn, will lower the strain on every organ in the body. It's almost as if the original developers of the first GLP-1 agonist had planned a series of sequels — they didn't invent drug repurposing. But — as we've noted above — drug repurposing is usually done by accident or in a moment of great desperation, such as the COVID-19 pandemic.
The BriefWire